Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

May 4, 2021

Study Completion Date

May 4, 2021

Conditions
Alpha1-Antitrypsin Deficiency
Interventions
DRUG

VX-864

Tablets for oral administration.

DRUG

Placebo

Placebo matched to VX-864 for oral administration.

Trial Locations (30)

11735

University of Florida, Gainesville

19140

Temple University Hospital, Philadelphia

22042

Inova Fairfax Medical Campus, Falls Church

27157

Wake Forest University Baptist Medical Center, Winston-Salem

27514

University of North Carolina Medical Center, Chapel Hill

29425

Medical University of South Carolina, Charleston

32803

Central Florida Pulmonary, Orlando

33136

University of Miami Miller School of Medicine, Miami

35233

University of Alabama at Birmingham, Birmingham

45229

University of Cincinnati, Cincinnati

52242

The University of Iowa Hospitals and Clinics, Iowa City

55455

University of Minnesota, Minneapolis

63104

Cardinal Glennon Children's Hospital - St. Louis University, St Louis

63401

Blessing Corporate Services, Inc., dba Blessing Health System, Hannibal

66160

University of Kansas Medical Center, Kansas City

75708

The University of Texas Health Science Center at Tyler, Tyler

77380

Renovatio Clinical, Houston

80206

National Jewish Health, Denver

84108

University of Utah Health, Salt Lake City

90095

David Geffen School of Medicine at UCLA, Los Angeles

95817

University of California Davis Medical Center, Sacramento

97239

Oregon Health & Science University, Portland

Unknown

Queen Elizabeth II Health Sciences Center, Halifax

Inspiration Research Ltd, Toronto

University Hospital RWTH Aachen, Aachen

Universitätsklinikum Essen, Essen

Medizinische Hochschule Hannover, Hanover

Royal College of Surgeons in Ireland Clinical Research Centre, Beaumont Hospital, Beaumont

Skanes Universitetssjukhus, Malmo, Malmo

Staploe Medical Centre, Soham Ely

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT04474197 - Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | Biotech Hunter | Biotech Hunter